1. Collaborative Osteonecrosis Group. Symptomatic Multifocal Osteonecrosis. Clin Orthop 1999; 369: 312–326.
2. Assouline-Dayan Y, Chang Ch, Greenspan A, Shoenfeld Y, et al. Pathogenesis and natural history of osteonecrosis. Seminars in Arthritis and Rheumatism 2002; 32(2): 94–124.
3. Clinkscales A, Cleary JD. Steroid induced avascular necrosis. Annals of Pharmacotherapy 2002; 36: 1105.
4. Pavelka K, Gatterová J, Sainerová A. Multiple osteonecroses in a patient with systemic connective tissue disease. Čes Revmatol 1999; 3: 142–145.
5. Griffith JF, Antonio GE, Kumta SM, et al. Osteonecrosis of hip and knee in patients with severe acute respiratory syndrome treated with steroids. Radiology 2005; 235: 168–175.
6. Chan MHM, Chan PKS, Griffith JF, Chan IHS, et al. Steroid-induced osteonecrosis in severe acute respiratory syndrome: a retrospective analysis of biochemical markers of bone metabolism and corticosteroid therapy. Pathology 2006; 38(3): 229–235.
7. Ce P, Gedizlioglu M, Gelal F, Coban P, et al. Avascular necrosis of the bones: an overlooked complication of pulse steroid tratment of multiple sclerosis. European Journal of Neurology 2006; 13: 857–861.
8. Torii Y, Hasegawa Y, Kubo T, Kodera Y, et al. Osteonecrosis of the femoral head after allogenic bone marrow transplantation. Clin Orthop 2001; 382: 124–132.
9. Sakamoto M, Shimizu K, Iida S, Akita T, et al. Osteonecrosis of the femoral head: a prospective study with MRI. J Bone Joint Surg Br 1997; 79: 213–219.
10. Nagasawa K, Tsukamoto H, Tada Y, Mayumi T, et al. Imaging study on the mode of development and changes in avascular necrosis of the femoral head in systemic lupus erythematosus: long term observations. Br J Rheumatol 1994; 33: 342–347.
11. Cosgriff SW. Thromboembolic complications associated with ACTH and cortisone therapy. Jama 1951; 147: 924–926.
12. Sjöberg HE, Blombäck M, Granberg PO. Thromboembolic complications, heparin treatment and increase in coagulation factors in Cushing’s syndrome. Acta Med Scand 1976; 199: 95–98.
13. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000; 342: 1792–801.
14. Brotman DJ, Girod JP, Posch A, Jani JT, et al. Effect of short-term glucocorticoids on hemostatic factors in healthy volunteers.Thromb Res 2006; 118: 247–252.
15. Frank FD. Effect of intravenous high-dose methylprednisolone on coagulation and fibrinolysis markers. Thromb Haemost 2005; 94: 466–468.
16. Yamamoto T, Irisa T, Sugioka Y, Sueishi K. Effects of pulse methylprednisolone on bone and marrow tissues. Arthritis Rheum 1997; 40(11): 2055–2064.
17. Miyanishi K, Yamamoto T, Irisa A, et al. Bone marrow fat cell enlargement and a rise in intraosseous pressure in steroid-treated rabbits with osteonecrosis. Bone 2002; 30(1): 185–190.
18. Wang GJ, Sweet DE, Reger Si, Thompson RC. Fat-cell changes as a mechanism of avascular necrosis of the femoral head in cortisone-treated rabbits. J Bone Joint Surg Am 1997; 59A: 729–735.
19. Kawai K, Tamaki A, Hirohata K. Steroid-induced accumulation of lipid in the osteocytes of the rabbit femoral head: a histological and electron micorscopic study. J Bone Joint Surg. Am 1985; 67A: 755–763.
20. Fisher DE, Bickel WH, Holley KE, Ellefson RD. Corticosteroid-induced aseptic necrosis. Clin Orthop 1972; 84: 200–206.
21. Gold EW, Fox OD, Wissfeld S, Curtiss PH. Corticosteroid-induced avascular necrosis: an experimental study in rabbits. Clin Orthop 1978; 135: 272–280.
22. Wang GJ, Lennox DW, Reger SI, Stamp WG, et al. Cortisone-induced intrafemoral head pressure change and its response to a drilling decompression method. Clin Orthop 1981; 159: 274–278.
23. Drescher W, Bünger MH, Weigert K, Bünger C, et al. Methylprednisolone enhances contraction of porcine femoral head epiphyseal arteries. Clin Orthop 2004; 423: 112–117.
24. Ichiseki T, Kaneuji A, Katsuda S, Ueda Y, et al. DNA oxidation injury in bone early after steroid administration is involved in the pathogenesis of steroid-induced osteonecrosis. Rheumatology 2005; 44: 456–460.
25. Ichiseki T, Matsumoto T, Nishino M, Kaneuji A, et al. Oxidative stress and vascular permeability in steroid-induced osteonecrosis model.J Orthop Sci 2004; 9(5): 509–515.
26. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanism of their deleterious effects on bone. J Clin Invest 1998; 102: 274–282.
27. Herkert O, KuhlH, Sandow J, Busse R, et al. Sex steroids used in hormonal treatment increase vascular procoagulant activity by inducing thrombin receptor (PAR 1) expression: role of the glucocorticoid receptor. Circulation 2001; 104: 2826–31.
28. Calvo-Alén J, McGwin G, Toloza S, Fernández M, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case-control study. Ann Rheum Dis 2006; 65: 785–790.
29. Nagasawa K, Tada Y, Koarada S, Horiuchi T, et al. Very early development of steroid-associated osteonecrosis of femoral head in systemic lupus erythematosus: prospective study by MRI. Lupus 2005; 14: 385–390.
30. Oinuma K, Harada Y, Nawata Y, Takabayashi K, et al. Osteonecrosis in patients with systemic lupus erythematosus develops very early after starting high dose corticosteroid treatment. Ann Rheum Dis 2001; 60: 1145–1148.
31. Massardo L, Jacobelli S, Leissner M, Gonzales M, Villarroel L, Rivero S. High-dose intravenous methylprednisolone therapy associated with osteonecrosis in patients with systemic lupus erythematosus. Lupus 1992; 1: 401–405.
32. Pavelka K. Osteonecrosis. Baillieres Best Pract Res Clin Rheumatol 2000; 14(2): 399–414.
33. Zizic TM, Marcoux C, Hungerford DS, Dansereau JV, Stevens MB. Corticosteroid therapy associated with ischemic necrosis of bone in systomic lupus erythematosus. Am J Med 1985; 789: 596–604.
34. Mok MY, Farewell VT, Isenberg DA. Risk factors for avascular necrosis of bone in patients with systemic lupus erythematosus: is there a role for antiphospholipid antibodies ?Ann Rheum Dis 2000; 59: 462–467.
35. Mok CC, Lau CS, Wong RW. Risk factors for avascular bone necrosis in systemic lupus erythematosus. Br J Rheumatol 1998; 37: 895–900.
36. Inoue A, Ono K. A histological study of idipathic avascular necrosis of the head of the femur. J Bone Joint Surg Br 1979; 61-B: 138–143.
37. Solomon L. Drug-induced arthropathy and necrosis of the femoral head. J Bone Joint Surg Br 1973; 55: 246–261.
38. Sakai T, Sugano N, Nishii T, Haraguchi K, et al. Bone scintigraphy for osteonecrosis of the knee in patients with non-traumatic osteonecrosis of the femoral head: comparison with magnetic resonance imaging. Ann Rheum Dis 2001; 60: 14–20.
39. Burgener FA, Meyers SP, Tan RK, Zanhbauer W. Differential diagnosis in magnetic resonance imaging.Thieme New York: Georg Thieme Verlag, 2002: 388.
40. Steinberg ME, Steinberg DR. Classification systems for osteonecrosis: an overview. Orthop Clin N Am 2004; 35: 273–283.
41. ARCO Comittee on Terminology and Staging. Report on the comittee meeting at Santiago de Compostella. ARCO Newsletter 1993; 5: 79–82.
42. Collaborative Osteonecrosis Group. Symptomatic Multifocal Osteonecrosis. Clin Orthop 1999; 369: 312–326.
43. LaPorte DM, Mont MA, Mohan V, Jonex LC, et al. Multifocal osteonecrosis. J Rheumatol 1998; 25: 1968–74.
44. Jacobs B. Epidemiology of traumatic and nontraumatic osteonecrosis. Clin Orthop 1978; 130: 51–67.
45. Sugano N, Nishii T, Shibuya T, et al. Contralateral hip in patients with unilateral nontraumatic osteonecrosis of the femoral head. Clin Orthop 1997; 334: 85–90.
46. Zizic TM, Marcoux C, Hungerford DS, Stevens MB. The early diagnosis of ischaemic necrosis of bone. Arthritis Rheum 1986; 29: 1177–1186.